Clinical Trial

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Study acronym: TELO - DMRD
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose : Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-02; most recent amendment 2025-03-30.
Status change: Not Yet Recruiting → Recruiting 2025-03-30
Trial Details
NCT Number NCT05530096
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions Multiple Myeloma
Enrollment 70 participants
Start Date 2024-05-01
Primary Completion 2027-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-04-03